mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2023-5-112-117mrj-1486Research ArticleОБЗОРЫREVIEWSАртропатия, ассоциированная с противоопухолевой терапией ингибиторами контрольных точек: текущее понимание проблемыArthropathy associated with antitumor checkpoint inhibitors therapy: current understanding of the problemhttps://orcid.org/0000-0003-0576-4870КолтаковаА. Д.KoltakovaA. D.

Анастасия Дмитриевна Колтакова

115522

Каширское шоссе, 34А

Москва

Anastasya Dmitrievna Koltakova

115522

34A, Kashirskoe Shosse

Moscow

koltakova.a.d@gmail.comhttps://orcid.org/0000-0002-6068-3080ЛилаА. М.LilaA. M.

115522

Каширское шоссе, 34А

кафедра ревматологии

125993

ул. Баррикадная, 2/1, стр. 1

Москва

115522

34A, Kashirskoe Shosse

Department of Rheumatology

125993

2/1, Barrikadnaya Street, Build. 1

Moscow

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian FederationФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияV.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of RussiaRussian Federation202318102023175112117Copyright © Колтакова А.Д., Лила А.М., 20232023Колтакова А.Д., Лила А.М.Koltakova A.D., Lila A.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1486

   Ингибиторы контрольных точек (ИКТ) – противоопухолевые препараты, активирующие иммунный ответ против клеток злокачественного новообразования. Терапия этими препаратами отличается высокой эффективностью, в то же время она ассоциируется с развитием множества иммуновоспалительных осложнений, в том числе скелетно-мышечных. В обзоре представлено текущее понимание клинических проявлений, патогенеза и терапии иммуноопосредованной артропатии у пациентов, получающих ИКТ.

   Checkpoint inhibitors (CPI) are anticancer drugs that activate the immune response against cancer cells. This type of treatment is highly effective, but also associates with many immunoinflammatory complications, including musculoskeletal. This review presents the current understanding of the clinical manifestations, pathogenesis and therapy of immune-mediated arthropathy in patients receiving CPI.

онкоревматологияингибиторы контрольных точекиммуноопосредованные нежелательные событияиммуноопосредованный артритoncorheumatologycheckpoint inhibitorsimmune-mediated adverse eventsimmune-mediated arthritisСтатья подготовлена в рамках научной темы № АААА-А19-119021190148-3. Исследование не имело спонсорской поддержкиThe article was published as part of scientific research topic № АААА-А19-119021190148-3. The investigation has not been sponsoredReferencesRobert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020 Jul 30;11(1):3801. doi: 10.1038/s41467-020-17670-y.Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020 Jul 30;11(1):3801. doi: 10.1038/s41467-020-17670-y.Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239.Cappelli LC, Gutierrez AK, Bingham CO. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. 3<sup>rd</sup>, Shah AA. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1751-1763. doi: 10.1002/acr.23177. Epub 2017 Sep 21.Cappelli LC, Gutierrez AK, Bingham CO. Rheumatic and Musculoskeletal Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature. 3<sup>rd</sup>, Shah AA. Arthritis Care Res (Hoboken). 2017 Nov;69(11):1751-1763. doi: 10.1002/acr.23177. Epub 2017 Sep 21.Zhang S, Zhou Z, Wang L, et al. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis. 2021 Feb 12;12:2040622320976996. doi: 10.1177/2040622320976996. eCollection 2021.Zhang S, Zhou Z, Wang L, et al. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Ther Adv Chronic Dis. 2021 Feb 12;12:2040622320976996. doi: 10.1177/2040622320976996. eCollection 2021.Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23.Kostine M, Finckh A, Bingham CO, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23.Ghosh N, Tiongson MD, Stewart C, et al. Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series. J Clin Rheumatol. 2021 Dec 1; 27(8):e317-e322. doi: 10.1097/RHU.0000000000001370.Ghosh N, Tiongson MD, Stewart C, et al. Checkpoint Inhibitor-Associated Arthritis: A Systematic Review of Case Reports and Case Series. J Clin Rheumatol. 2021 Dec 1; 27(8):e317-e322. doi: 10.1097/RHU.0000000000001370.Manzo C, Isetta M, Natale M, Castagna A. Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature. Medicines (Basel). 2020 Nov 3;7(11):68. doi: 10.3390/medicines7110068.Manzo C, Isetta M, Natale M, Castagna A. Identification and Classification of Polymyalgia Rheumatica (PMR) and PMR-Like Syndromes Following Immune Checkpoint Inhibitors (ICIs) Therapy: Discussion Points and Grey Areas Emerging from a Systematic Review of Published Literature. Medicines (Basel). 2020 Nov 3;7(11):68. doi: 10.3390/medicines7110068.Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.Cappelli LC, Brahmer JR, Forde PM, et al. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Semin Arthritis Rheum. 2018 Dec;48(3):553-557. doi: 10.1016/j.semarthrit.2018.02.011. Epub 2018 Mar 22.Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995 Nov;3(5):541-7. doi: 10.1016/1074-7613(95)90125-6.Tivol EA, Borriello F, Schweitzer AN, et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 1995 Nov;3(5):541-7. doi: 10.1016/1074-7613(95)90125-6.Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995 Nov 10;270(5238):985-8. doi: 10.1126/science.270.5238.985.Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995 Nov 10;270(5238):985-8. doi: 10.1126/science.270.5238.985.Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2383-92. doi: 10.1073/pnas.1603892113. Epub 2016 Apr 11.Klocke K, Sakaguchi S, Holmdahl R, Wing K. Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. Proc Natl Acad Sci U S A. 2016 Apr 26;113(17):E2383-92. doi: 10.1073/pnas.1603892113. Epub 2016 Apr 11.Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999 Aug;11(2):141-51. doi: 10.1016/s1074-7613(00)80089-8.Nishimura H, Nose M, Hiai H, et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999 Aug;11(2):141-51. doi: 10.1016/s1074-7613(00)80089-8.Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010 Jul;62(7):1870-80. doi: 10.1002/art.27500.Raptopoulou AP, Bertsias G, Makrygiannakis D, et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum. 2010 Jul;62(7):1870-80. doi: 10.1002/art.27500.Murray-Brown W, Wilsdon TD, Weedon H, et al. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J Immunother Cancer. 2020 Jun;8(1):e000281. doi: 10.1136/jitc-2019-000281.Murray-Brown W, Wilsdon TD, Weedon H, et al. Nivolumab-induced synovitis is characterized by florid T cell infiltration and rapid resolution with synovial biopsy-guided therapy. J Immunother Cancer. 2020 Jun;8(1):e000281. doi: 10.1136/jitc-2019-000281.Kim ST, Chu Y, Misoi M, et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 Apr 12;13(1):1970. doi: 10.1038/s41467-022-29539-3.Kim ST, Chu Y, Misoi M, et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022 Apr 12;13(1):1970. doi: 10.1038/s41467-022-29539-3.Yan Y, Cao S, Liu X, et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018 Apr 19;3(8):e97828. doi: 10.1172/jci.insight.97828.Yan Y, Cao S, Liu X, et al. CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. JCI Insight. 2018 Apr 19;3(8):e97828. doi: 10.1172/jci.insight.97828.Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.Johnson DB, Balko JM, Compton ML, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.Läubli H, Koelzer VH, Matter MS, et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology. 2017 Oct 26;7(2):e1386362. doi: 10.1080/2162402X.2017.1386362. eCollection 2018.Läubli H, Koelzer VH, Matter MS, et al. The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors. Oncoimmunology. 2017 Oct 26;7(2):e1386362. doi: 10.1080/2162402X.2017.1386362. eCollection 2018.Robert L, Tsoi J, Wang X. et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 1;20(9):2424-32. doi: 10.1158/1078-0432.CCR-13-2648. Epub 2014 Feb 28.Robert L, Tsoi J, Wang X. et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire. Clin Cancer Res. 2014 May 1;20(9):2424-32. doi: 10.1158/1078-0432.CCR-13-2648. Epub 2014 Feb 28.Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017 Mar 15;77(6):1322-1330. doi: 10.1158/0008-5472.CAN-16-2324. Epub 2016 Dec 28.Oh DY, Cham J, Zhang L, et al. Immune toxicities elicted by CTLA-4 blockade in cancer patients are associated with early diversification of the T-cell repertoire. Cancer Res. 2017 Mar 15;77(6):1322-1330. doi: 10.1158/0008-5472.CAN-16-2324. Epub 2016 Dec 28.Calabrese L, Mariette X. Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications. Ann Rheum Dis. 2020 Mar;79(3):309-311. doi: 10.1136/annrheumdis-2019-216510. Epub 2020 Jan 3.Calabrese L, Mariette X. Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications. Ann Rheum Dis. 2020 Mar;79(3):309-311. doi: 10.1136/annrheumdis-2019-216510. Epub 2020 Jan 3.Chan KK, Tirpack A, Vitone G, et al. Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry. ACR Open Rheumatol. 2020 Oct;2(10):595-604. doi: 10.1002/acr2.11181. Epub 2020 Oct 3.Chan KK, Tirpack A, Vitone G, et al. Higher Checkpoint Inhibitor Arthritis Disease Activity may be Associated With Cancer Progression: Results From an Observational Registry. ACR Open Rheumatol. 2020 Oct;2(10):595-604. doi: 10.1002/acr2.11181. Epub 2020 Oct 3.Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020 Mar;79(3):332-338. doi: 10.1136/annrheumdis-2019-216109. Epub 2019 Sep 20.Braaten TJ, Brahmer JR, Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020 Mar;79(3):332-338. doi: 10.1136/annrheumdis-2019-216109. Epub 2019 Sep 20.Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.Schneider BJ, Naidoo J, Santomasso BD, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1.Draghi A, Borch TH, Radic HD, et al. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int J Cancer. 2019 Sep 1;145(5):1408-1413. doi: 10.1002/ijc.32080. Epub 2019 Jan 7.Draghi A, Borch TH, Radic HD, et al. Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: implications for the management of irAEs. Int J Cancer. 2019 Sep 1;145(5):1408-1413. doi: 10.1002/ijc.32080. Epub 2019 Jan 7.Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed Death-Ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.Arbour KC, Mezquita L, Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed Death-Ligand 1 blockade in patients with non-small-cell lung cancer. J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.Maslov DV, Tawagi K, Kc M, et al. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer. 2021 Jul;9(7):e002261. doi: 10.1136/jitc-2020-002261.Maslov DV, Tawagi K, Kc M, et al. Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer. J Immunother Cancer. 2021 Jul;9(7):e002261. doi: 10.1136/jitc-2020-002261.Drakaki A, Dhillon PK, Wakelee H, et al. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. Oncoimmunology. 2020 Oct 5;9(1):1824645. doi: 10.1080/2162402X.2020.1824645.Drakaki A, Dhillon PK, Wakelee H, et al. Association of baseline systemic corticosteroid use with overall survival and time to next treatment in patients receiving immune checkpoint inhibitor therapy in real-world US oncology practice for advanced non-small cell lung cancer, melanoma, or urothelial carcinoma. Oncoimmunology. 2020 Oct 5;9(1):1824645. doi: 10.1080/2162402X.2020.1824645.De Giglio A, Mezquita L, Auclin E, et al. Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-Small-Cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI). Cancers (Basel). 2020 Sep 30;12(10):2827. doi: 10.3390/cancers12102827.De Giglio A, Mezquita L, Auclin E, et al. Impact of intercurrent introduction of steroids on clinical outcomes in advanced non-Small-Cell lung cancer (NSCLC) patients under immune-checkpoint inhibitors (ICI). Cancers (Basel). 2020 Sep 30;12(10):2827. doi: 10.3390/cancers12102827.Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018 Nov;13(11):1771-1775. doi: 10.1016/j.jtho.2018.06.004. Epub 2018 Jun 20.Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol. 2018 Nov;13(11):1771-1775. doi: 10.1016/j.jtho.2018.06.004. Epub 2018 Jun 20.Riudavets M, Mosquera J, Garcia-Campelo R, et al. Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-(L)1 blockade agents. Front Oncol. 2020 Sep 7;10:1677. doi: 10.3389/fonc.2020.01677. eCollection 2020.Riudavets M, Mosquera J, Garcia-Campelo R, et al. Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-(L)1 blockade agents. Front Oncol. 2020 Sep 7;10:1677. doi: 10.3389/fonc.2020.01677. eCollection 2020.Bruera S, Suarez-Almazor ME. The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol. 2022 Aug 23;12:928390. doi: 10.3389/fonc.2022.928390. eCollection 2022.Bruera S, Suarez-Almazor ME. The effects of glucocorticoids and immunosuppressants on cancer outcomes in checkpoint inhibitor therapy. Front Oncol. 2022 Aug 23;12:928390. doi: 10.3389/fonc.2022.928390. eCollection 2022.Paderi A, Gambale E, Botteri C, et al. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules. 2021 Sep 24;26(19):5789. doi: 10.3390/molecules26195789.Paderi A, Gambale E, Botteri C, et al. Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules. 2021 Sep 24;26(19):5789. doi: 10.3390/molecules26195789.Petrelli F, Signorelli D, Ghidini M, et al. Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020 Feb 27;12(3):546. doi: 10.3390/cancers12030546.Petrelli F, Signorelli D, Ghidini M, et al. Association of Steroids use with Survival in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Cancers (Basel). 2020 Feb 27;12(3):546. doi: 10.3390/cancers12030546.Ricciuti B, Dahlberg SE, Adeni A, et al. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 Aug 1;37(22):1927-1934. doi: 10.1200/JCO.19.00189. Epub 2019 Jun 17.Ricciuti B, Dahlberg SE, Adeni A, et al. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications. J Clin Oncol. 2019 Aug 1;37(22):1927-1934. doi: 10.1200/JCO.19.00189. Epub 2019 Jun 17.Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018 Sep 15;124(18):3706-3714. doi: 10.1002/cncr.31629. Epub 2018 Jul 5.Faje AT, Lawrence D, Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018 Sep 15;124(18):3706-3714. doi: 10.1002/cncr.31629. Epub 2018 Jul 5.Leipe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018 Aug 17;4(2):e000714. doi: 10.1136/rmdopen-2018-000714. eCollection 2018.Leipe J, Christ LA, Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018 Aug 17;4(2):e000714. doi: 10.1136/rmdopen-2018-000714. eCollection 2018.Brynjarsdottir HB, Bjursten S, Levin M, et al. Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment. J Rheumatol. 2023 Sep;50(9):1195-1197. doi: 10.3899/jrheum.221182. Epub 2023 Apr 1.Brynjarsdottir HB, Bjursten S, Levin M, et al. Successful Management of Checkpoint Inhibitor-Induced Arthritis With Disease-Modifying Antirheumatic Drugs During Active Immune Checkpoint Inhibition Treatment. J Rheumatol. 2023 Sep;50(9):1195-1197. doi: 10.3899/jrheum.221182. Epub 2023 Apr 1.Ford M, Sahbudin I, Filer A, et al. High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis. Rheumatology (Oxford). 2018 Dec 1;57(12):2244-2246. doi: 10.1093/rheumatology/key234.Ford M, Sahbudin I, Filer A, et al. High proportion of drug hypersensitivity reactions to sulfasalazine following its use in anti-PD-1-associated inflammatory arthritis. Rheumatology (Oxford). 2018 Dec 1;57(12):2244-2246. doi: 10.1093/rheumatology/key234.Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312(5996):724-9. doi: 10.1038/312724a0.Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature. 1984;312(5996):724-9. doi: 10.1038/312724a0.Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70. doi: 10.1073/pnas.72.9.3666.Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3666-70. doi: 10.1073/pnas.72.9.3666.Micic D, Komaki Y, Alavanja A, et al. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 Jan;53(1):e1-e11. doi: 10.1097/MCG.0000000000000865.Micic D, Komaki Y, Alavanja A, et al. Risk of Cancer Recurrence Among Individuals Exposed to Antitumor Necrosis Factor Therapy: A Systematic Review and Meta-Analysis of Observational Studies. J Clin Gastroenterol. 2019 Jan;53(1):e1-e11. doi: 10.1097/MCG.0000000000000865.De Queiroz MJ, de Castro CT, Albuquerque FC, et al. Safety of biological therapy in patients with rheumatoid arthritis in administrative health databases: A systematic review and meta-analysis. Front Pharmacol. 2022 Aug 11;13:928471. doi: 10.3389/fphar.2022.928471. eCollection 2022.De Queiroz MJ, de Castro CT, Albuquerque FC, et al. Safety of biological therapy in patients with rheumatoid arthritis in administrative health databases: A systematic review and meta-analysis. Front Pharmacol. 2022 Aug 11;13:928471. doi: 10.3389/fphar.2022.928471. eCollection 2022.Montfort A, Colacios C, Levade T, et al. The TNF Paradox in Cancer Progression and Immunotherapy. Front Immunol. 2019 Jul 31;10:1818. doi: 10.3389/fimmu.2019.01818. eCollection 2019.Montfort A, Colacios C, Levade T, et al. The TNF Paradox in Cancer Progression and Immunotherapy. Front Immunol. 2019 Jul 31;10:1818. doi: 10.3389/fimmu.2019.01818. eCollection 2019.Bertrand F, Montfort A, Marcheteau E, et al. TNF blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.Bertrand F, Montfort A, Marcheteau E, et al. TNF blockade overcomes resistance to anti-PD-1 in experimental melanoma. Nat Commun. 2017 Dec 22;8(1):2256. doi: 10.1038/s41467-017-02358-7.Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. Nature. 2019 May;569(7756):428-432. doi: 10.1038/s41586-019-1162-y. Epub 2019 May 1.Meyer N, Lusque A, Virazels M, et al. Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial. Annals of Oncology. 2022;33 (suppl_7): S356-S409. URL: https://www.annalsofoncology.org/article/S0923-7534(22)02823-X/fulltext.Meyer N, Lusque A, Virazels M, et al. Triple combination of ipilimumab + nivolumab + anti-TNF in treatment naive melanoma patients: Final analysis of TICIMEL, a phase Ib prospective clinical trial. Annals of Oncology. 2022;33 (suppl_7): S356-S409. URL: https://www.annalsofoncology.org/article/S0923-7534(22)02823-X/fulltext.Montfort A, Filleron T, Virazels M, et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res. 2021 Feb 15;27(4):1037-1047. doi: 10.1158/1078-0432.CCR-20-3449. Epub 2020 Dec 3.Montfort A, Filleron T, Virazels M, et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res. 2021 Feb 15;27(4):1037-1047. doi: 10.1158/1078-0432.CCR-20-3449. Epub 2020 Dec 3.Hailemichael Y, Johnson DH, Abdel-Wahab N, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 May 9;40(5):509-523.e6. doi: 10.1016/j.ccell.2022.04.004. Epub 2022 May 9.Hailemichael Y, Johnson DH, Abdel-Wahab N, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 May 9;40(5):509-523.e6. doi: 10.1016/j.ccell.2022.04.004. Epub 2022 May 9.Weber JS, Muramatsu T, Hamid O, et al. Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma. Annals of Oncology. 2021;32 (suppl_5):S867-S905. URL: https://www.annalsofoncology.org/article/S0923-7534(21)03654-1/fulltext.Weber JS, Muramatsu T, Hamid O, et al. Phase II trial of ipilimumab, nivolumab and tocilizumab for unresectable metastatic melanoma. Annals of Oncology. 2021;32 (suppl_5):S867-S905. URL: https://www.annalsofoncology.org/article/S0923-7534(21)03654-1/fulltext.Bass AR, Abdel-Wahab N, Reid PD, et al. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 Jul;82(7):920-926. doi: 10.1136/ard-2023-223885. Epub 2023 Apr 5.Bass AR, Abdel-Wahab N, Reid PD, et al. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023 Jul;82(7):920-926. doi: 10.1136/ard-2023-223885. Epub 2023 Apr 5.Ma VT, Lao CD, Fecher LA, Schiopu E. Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy. 2022 Jun;14(8):593-598. doi: 10.2217/imt-2021-0274. Epub 2022 Apr 13.Ma VT, Lao CD, Fecher LA, Schiopu E. Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy. 2022 Jun;14(8):593-598. doi: 10.2217/imt-2021-0274. Epub 2022 Apr 13.De La Fuente F, Belkhir R, Henry J, et al. Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. RMD Open. 2022 Oct;8(2):e002612. doi: 10.1136/rmdopen-2022-002612.De La Fuente F, Belkhir R, Henry J, et al. Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. RMD Open. 2022 Oct;8(2):e002612. doi: 10.1136/rmdopen-2022-002612.Murray K, Floudas A, Murray C, et al. First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. BMJ Case Rep. 2021 Feb 4;14(2):e238851. doi: 10.1136/bcr-2020-238851.Murray K, Floudas A, Murray C, et al. First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. BMJ Case Rep. 2021 Feb 4;14(2):e238851. doi: 10.1136/bcr-2020-238851.

The authors declare that there are no conflicts of interest present.